关键词：黄斑；小面积；视网膜；眼睛黄斑；退化；AMD
摘 要：The macula is a small area in the retina that is responsible for the central vision. AMD is defined as the deterioration of the eye's macula. The exact etiology of AMD is unknown. There are two types of AMD: wet and dry. Wet AMD occurs when tiny abnormal blood vessels begin growing behind the retina, toward the macula, while dry AMD occurs when small, yellowish deposits called drusen begin accumulating beneath the macula. While a number of treatments are available for wet AMD, there is no treatment available at the moment for dry AMD.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

03.2.1 Product Profiles

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Product Portfolio of Current AMD Therapies

08. Clinical Pipeline Portfolio

09. Rate of Incidence and Prevalence

09.1.1 US

09.1.2 UK

09.1.3 Australia

09.1.4 Japan

09.1.5 China

09.1.6 India

10. Market Segmentation by Type

11. Geographical Segmentation

11.1 AMD Market in the Americas

11.1.1 Market Size and Forecast

11.2 AMD Market in the EMEA Region

11.2.1 Market Size and Forecast

11.3 AMD Market in the APAC Region

11.3.1 Market Size and Forecast

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

19.1 Competitive Scenario

19.1.1 Key News

19.1.2 Mergers and Acquisitions

19.2 Market Analysis 2013

19.3 Other Prominent Vendors

19.4 Future Vendors Expected To Tap AMD Market

20. Key Vendor Analysis

20.1 Bayer AG

20.1.1 Key Facts

20.1.2 Business Overview

20.1.3 Business Segmentation

20.1.4 Revenue by Business Segmentation 2012 and 2013

20.1.5 Sales by Geography

20.1.6 Business Strategy

20.1.7 Key Information

20.1.8 SWOT Analysis

20.1.9 Strengths

20.1.10 Weaknesses

20.1.11 Opportunities

20.1.12 Threats

20.2 F. Hoffmann-La Roche Ltd.

20.2.1 Key Facts

20.2.2 Business Overview

20.2.3 Business Segmentation

20.2.4 Revenue by Business Segmentation 2012 and 2013

20.2.5 Sales by Geography

20.2.6 Business Strategy

20.2.7 Key Information

20.2.8 SWOT Analysis

20.2.9 Strengths

20.2.10 Weaknesses

20.2.11 Opportunities

20.2.12 Threats

20.3 Novartis AG

20.3.1 Key Facts

20.3.2 Business Overview

20.3.3 Business Segmentation 9

20.3.4 Revenue by Business Segmentation

20.3.5 Revenue Comparison by Business Segmentation 2012 and

2013

20.3.6 Sales by Geography

20.3.7 Business Strategy

20.3.8 Key Developments

20.3.9 SWOT Analysis

20.3.10 Strengths

20.3.11 Weaknesses

20.3.12 Opportunities

20.3.13 Threats

20.4 Regeneron Pharmaceuticals Inc.

20.4.1 Key Facts

20.4.2 Business Overview

20.4.3 Product Offerings

20.4.4 Revenue by Product Segmentation 2013

20.4.5 Business Strategy

20.4.6 Key Information

20.4.7 SWOT Analysis

20.4.8 Strengths

20.4.9 Weaknesses

20.4.10 Opportunities

20.4.11 Threats

21. Other Reports in this Series